Herpes Zoster - Causes, Treatment & When to See a Doctor

```html

What is Herpes Zoster?

Herpes zoster, commonly called shingles, is a painful skin rash caused by the re‑activation of the varicella‑zoster virus (VZV), the same virus that produces chickenpox. After a person recovers from chickenpox, VZV remains dormant in nerve ganglia. Years or decades later, the virus can reactivate, travel along sensory nerves, and produce a characteristic unilateral rash that typically follows a dermatomal (band‑like) distribution. The condition is most common in adults over age 50, but it can affect anyone who has had chickenpox, including children and immunocompromised patients.

According to the CDC, about 1 in 3 people in the United States will develop shingles in their lifetime.

Common Causes

Herpes zoster itself is not caused by multiple separate conditions; rather, it results from virus reactivation that can be triggered by a variety of risk factors and underlying states. The most common precipitants include:

• Age‑related decline in immunity – Immune surveillance wanes after age 50, making reactivation more likely.
• Immunosuppression – HIV infection, organ transplantation, chemotherapy, biologic agents (e.g., TNF‑α inhibitors), and long‑term corticosteroid use.
• Stress – Physical or emotional stress can blunt cellular immunity.
• Recent illness or fever – Respiratory infections, influenza, or other systemic illnesses.
• Radiation therapy – Especially when directed at areas of the body that contain sensory nerves.
• Autoimmune diseases – Rheumatoid arthritis, systemic lupus erythematosus, and others.
• Trauma to a dermatome – Surgery or injury may precipitate reactivation in the affected nerve distribution.
• Medication that lowers T‑cell function – E.g., azathioprine, mycophenolate, and certain antimetabolites.
• Malnutrition – Particularly deficiencies in vitamins A, C, D, or zinc that affect immune function.
• Smoking – Chronic tobacco use is linked to reduced cell‑mediated immunity.

Associated Symptoms

Shingles usually begins with a prodrome of non‑specific symptoms, followed by the classic rash. Common manifestations are:

• Prodromal pain – Burning, throbbing, or aching sensation in the affected dermatome, often before any rash appears.
• Itching or tingling (paresthesia)
• Fever, chills, or malaise – Usually mild but can be more pronounced in older adults.
• Rash – Red patches that evolve into fluid‑filled vesicles, typically grouped in a band‑shaped pattern.
• Post‑herpetic neuralgia (PHN) – Persistent nerve pain lasting weeks to months after the rash resolves; occurs in ~10–15 % of patients over 60.
• Ocular involvement – When the ophthalmic branch of the trigeminal nerve is affected (herpes‑zoster ophthalmicus), patients may experience eye redness, vision changes, or photophobia.
• Hearing loss or vertigo – In Ramsay Hunt syndrome (facial nerve involvement), ear pain, vesicles on the ear canal, and facial weakness can occur.
• Generalized weakness or lymphadenopathy – May be present, especially in immunocompromised hosts.

When to See a Doctor

Early medical evaluation is crucial, because antiviral therapy is most effective when started within 72 hours of rash onset. Seek care promptly if you notice any of the following:

• Rash that follows a single dermatome, especially on the face, chest, or around the eye.
• Severe or worsening pain that does not improve with over‑the‑counter analgesics.
• Fever > 101 °F (38.3 °C) with rash.
• Blurred vision, eye redness, or new visual disturbances.
• Rash on the tip of the nose (Hutchinson’s sign) – a red flag for ocular involvement.
• Facial weakness, ear pain, or vesicles in the ear canal (possible Ramsay Hunt syndrome).
• Immunocompromised conditions (e.g., HIV, recent transplant, chemotherapy).
• Any rash that spreads beyond one dermatome or appears in multiple, non‑contiguous areas.

Diagnosis

Diagnosis is usually clinical, based on the characteristic appearance of the rash and its distribution. However, certain situations warrant laboratory confirmation.

Clinical Evaluation

• History – Prior chickenpox infection or varicella vaccination, recent stressors, immunosuppressive medications.
• Physical exam – Observation of a unilateral, vesicular rash in a dermatomal pattern; assessment of pain severity.

Laboratory & Imaging Tests

• Polymerase chain reaction (PCR) of vesicle fluid – Highly sensitive and specific for VZV DNA.
• Tzanck smear – Shows multinucleated giant cells but cannot differentiate VZV from HSV.
• Serology – Not routinely used; IgM may indicate recent infection but is less reliable.
• Ophthalmic examination – Slit‑lamp exam if ocular involvement is suspected.
• Imaging (MRI/CT) – Reserved for complicated cases with neurological deficits, to evaluate for encephalitis or spinal cord involvement.

Treatment Options

The main goals of therapy are to reduce viral replication, shorten the rash duration, lessen pain, and prevent complications such as post‑herpetic neuralgia.

Antiviral Medications (first‑line)

• Acyclovir 800 mg five times daily for 7–10 days.
• Valacyclovir 1 g three times daily for 7 days (more convenient dosing).
• Famciclovir 500 mg three times daily for 7 days.

All are most effective when started within 72 hours of rash onset. In immunocompromised patients, treatment may be extended to 14–21 days and intravenous acyclovir may be required.

Pain Management

• Over‑the‑counter analgesics – Acetaminophen or ibuprofen.
• Topical agents – Lidocaine 5 % patches or creams, capsaicin.
• Prescription neuropathic pain drugs – Gabapentin, pregabalin, or tricyclic antidepressants for PHN.
• Short course of oral steroids – Controversial; may reduce acute pain and inflammation but not routinely recommended.

Adjunctive Care

• Cool compresses – Alleviate itching and discomfort.
• Calamine lotion or oatmeal baths – Provide soothing relief.
• Good skin hygiene – Keep lesions clean and covered to prevent bacterial superinfection.

Hospitalization

Indicated for patients with:

• Disseminated zoster (lesions beyond a single dermatome).
• Ocular involvement (herpes‑zoster ophthalmicus).
• Severe immunosuppression.
• Neurological complications (e.g., meningitis, myelitis, encephalitis).

Prevention Tips

Because shingles results from reactivation of a latent virus, the most effective preventive strategies focus on immunity enhancement and vaccination.

• Shingles vaccine – Two FDA‑approved vaccines:
  • Shingrix (recombinant zoster vaccine, RZV): 2 doses, 2–6 months apart; >90 % efficacy in adults ≥50 years and in immunocompromised groups.
  • Zostavax (live‑attenuated vaccine): Less effective, now generally replaced by Shingrix.
• Varicella (chickenpox) vaccine in childhood to prevent primary infection.
• Maintain a healthy immune system:
  • Balanced diet rich in fruits, vegetables, and lean protein.
  • Regular moderate‑intensity exercise (150 min/week).
  • Adequate sleep (7–9 hours per night).
  • Stress‑reduction techniques (mindfulness, yoga).
• Avoid smoking and limit alcohol consumption – both impair immune function.
• Promptly treat any acute illness (e.g., flu) to minimize immune stress.
• For immunocompromised patients, discuss timing of vaccination with an infectious‑disease specialist.

Emergency Warning Signs

---

**References**

• Mayo Clinic. “Shingles (Herpes Zoster).” https://www.mayoclinic.org
• Centers for Disease Control and Prevention. “Shingles (Herpes Zoster).” https://www.cdc.gov
• National Institutes of Health, National Institute of Allergy and Infectious Diseases. “Shingles Vaccine.” https://www.niaid.nih.gov
• World Health Organization. “Varicella Zoster Virus.” https://www.who.int
• Cleveland Clinic. “Postherpetic Neuralgia.” https://my.clevelandclinic.org
• Thompson, A. M., et al. “Efficacy of the Recombinant Zoster Vaccine in Adults 50 Years of Age or Older.” *New England Journal of Medicine*, 2020.

```